Publisher： Adis International
ISSN： 1173-5503
Source： PharmacoEconomics and Outcomes News, Vol.1, Iss.670, 2013-01, pp. : 6-6
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content
Genetic testing good to guide thienopyridine treatment
PharmacoEconomics and Outcomes News, Vol. 1, Iss. 664, 2012-01 ,pp. :
Access to resources
Recommend
Tamoxifen a worthwhile investment for women at risk for breast cancer
PharmacoEconomics and Outcomes News, Vol. 1, Iss. 252, 2000-01 ,pp. :
Dose-intensified chemotherapy in breast cancer not worthwhile
Inpharma, Vol. 1, Iss. 1388, 2003-01 ,pp. :
Tamoxifen a worthwhile investment for women at risk for breast cancer
Inpharma, Vol. 1, Iss. 1227, 2000-01 ,pp. :
Is genetic testing to guide cancer therapy cost effective?
PharmacoEconomics and Outcomes News, Vol. 1, Iss. 630, 2011-01 ,pp. :